Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 06/20 01:42:59 pm
79.815 USD   +0.47%
01:39pACCELERON PHARM : Announces Updated Results from Ongoing Phase 2 Tri..
AQ
06/19CELGENE CORPORA : Announces Appointment of Jonathan Biller as Execut..
BU
06/19NASDAQ 100 MOVE : Jd, regn
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Business Summary
Logo Celgene Corporation
Develops human pharmaceuticals and agrochemicals

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases.

Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax.

Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Number of employees : 7 467 persons.
Sales per Businesses
20162017Delta
USD (in Million)%USD (in Million)%
Biopharmaceuticals - Net Product Sales - REVLIMID6,97463.8%8,18763.9% +17.4%
Biopharmaceuticals - Net Product Sales - POMALYST/IMNOVID1,31112%1,61412.6% +23.14%
Biopharmaceuticals - Net Product Sales - OTEZLA1,0179.3%1,27910% +25.74%
Biopharmaceuticals - Net Product Sales - ABRAXANE973.408.9%992.007.7% +1.91%
Biopharmaceuticals - Net Product Sales - VIDAZA608.005.6%628.004.9% +3.29%
Biopharmaceuticals - Net Product Sales - THALOMID152.101.4%132.001% -13.21%
Biopharmaceuticals - Net Product Sales - ISTODAX79.300.7%76.000.6% -4.16%
Biopharmaceuticals - Net Product Sales - Azacitidine for Inj66.000.6%36.000.3% -45.45%
Biopharmaceuticals - Net Product Sales - Other Revenue44.600.4%---
Biopharmaceuticals - Net Product Sales - Other4.300%---
Other--39.000.3%-
Biopharmaceuticals - Net Product Sales - IDHIFA--20.000.2%-
Sales per Regions
20162017Delta
USD (in Million)%USD (in Million)%
United States7,01064.2%8,32464.9% +18.75%
Europe3,04627.9%3,32725.9% +9.21%
All Other1,17310.7%1,35210.5% +15.23%
Managers
NameAgeSinceTitle
Mark Alles592004Chairman, President, CEO & COO
Peter N. Kellogg, MBA622014Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo, MD63-Senior Vice President-Global Medical Affairs
Jay T. Backstrom, MD-2008Chief Medical Officer
Rupert J. Vessey, PhD532015President-Research & Early Development
Michael D. Casey722002Lead Independent Director
James J. Loughlin, CPA752007Independent Director
Ernest Mario, PhD792007Independent Director
Carrie Smith Cox612009Independent Director
Michael A. Friedman, MD742011Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 966,127,113 722,347,569 74.8% 241,300,000 25.0% 74.8%
Shareholders
NameEquities%
The Vanguard Group, Inc. 52,677,136 7.27%
BlackRock Fund Advisors 41,567,382 5.73%
SSgA Funds Management, Inc. 30,204,281 4.17%
Edgewood Management LLC 11,980,937 1.65%
Northern Trust Investments, Inc. 9,626,699 1.33%
Henderson Global Investors Ltd. 9,439,063 1.30%
Jennison Associates LLC 8,767,112 1.21%
Geode Capital Management LLC 8,697,801 1.20%
Deutsche Asset Management Investment GmbH 7,662,981 1.06%
Norges Bank Investment Management 6,904,337 0.95%
Holdings
NameEquities%Valuation
Agios Pharmaceuticals Inc (AGIO) 6,718,43311.7%628,173,486 USD
BEIGENE LTD COM 32,746,41610.4%503,942,127 USD
Acceleron Pharma Inc (XLRN) 6,118,47913.4%217,450,744 USD
Crispr Therapeutics AG (CRSP) 2,800,7725.94%193,001,199 USD
Epizyme Inc (EPZM) 3,674,6405.29%64,122,468 USD
Atara Biotherapeutics Inc (ATRA) 1,154,5402.63%57,496,092 USD
Jounce Therapeutics Inc (JNCE) 3,456,46310.6%38,885,209 USD
Zymeworks Inc (ZYME) 1,539,4836.05%31,713,350 USD
Oncomed Pharmaceuticals Inc (OMED) 2,970,5887.73%9,238,529 USD
Alliqua Biomedical Inc (ALQA) 804,61016.1%1,689,681 USD
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- Nasdaq 100 / SP 100, SP 500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50
Stock Exchange Codes
- Bloomberg Code :  CELG:US
- Reuters Code :  CELG.O
- Datastream Code :  
Company contact information
Celgene Corporation
86 avenue Morris
NJ 07901 Summit, New Jersey
États-Unis (les)

Phone : +1 908 673 9000
Fax : +1
Internet : http://www.celgene.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
CELGENE CORPORATION-25.52%56 341
JOHNSON & JOHNSON-13.17%325 398
PFIZER-0.17%211 520
NOVARTIS-8.25%188 977
ROCHE HOLDING LTD.-14.38%182 331
MERCK AND COMPANY8.46%164 082
AMGEN5.78%121 721
ABBOTT LABORATORIES10.23%110 135
BAYER-2.22%106 282
GLAXOSMITHKLINE17.20%101 387
SANOFI-4.41%98 673
ELI LILLY AND COMPANY2.87%93 466
ASTRAZENECA4.73%90 289
BRISTOL-MYERS SQUIBB COMPANY-12.45%87 693
NOVO NORDISK A/S-13.90%85 401
ALLERGAN PLC5.87%58 224
SHIRE2.00%48 412
JIANGSU HENGRUI MEDICINE CO LTD43.14%43 187
ASTELLAS PHARMA INC19.45%31 115
TAKEDA PHARMACEUTICAL CO LTD-35.34%30 308
CHUGAI PHARMACEUTICAL CO LTD2.43%30 014
Connections : Celgene Corporation
European Federation of Pharmaceutical Industries & Assns
PharmAkea, Inc.
California Institute for Regenerative Medicine
Orbus Therapeutics, Inc.
University of Pennsylvania Museum of Archaeology & Anthropolog
Taxis Pharmaceuticals, Inc.
Tulane University (Louisiana)
Sidecar Therapeutics, Inc.
American College of Physicians Foundation
Gilda's Club New York City, Inc.
Humacyte, Inc.
Mali Health Organizing Project
HealthCare Institute of New Jersey
Pharmaceutical Research & Manufacturers of America
Rosemont College
Biotechnology Innovation Organization
Receptos, Inc.
Rutgers University Foundation
Smith & Nephew A/S (Denmark)
Gladstone Foundation (CA)
City of Hope National Medical Center
© 2018 People , Fundamentals and Ownership    © 2018 Cofisem